JO3624B1 - تركيبات إنسولين سريعة المفعول - Google Patents

تركيبات إنسولين سريعة المفعول

Info

Publication number
JO3624B1
JO3624B1 JOP/2015/0079A JOP20150079A JO3624B1 JO 3624 B1 JO3624 B1 JO 3624B1 JO P20150079 A JOP20150079 A JO P20150079A JO 3624 B1 JO3624 B1 JO 3624B1
Authority
JO
Jordan
Prior art keywords
rapid
acting insulin
insulin compositions
insulin analog
insulin
Prior art date
Application number
JOP/2015/0079A
Other languages
English (en)
Inventor
Edward CHRISTE Michael
Andrew HARDY Thomas
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53189204&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3624(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of JO3624B1 publication Critical patent/JO3624B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

يتعلق الاختراع الحالي بتركيبة إنسولين بشري أو نظير إنسولين تتضمن تربروستينيل ولها مفعول دوأئي أسرع من الصيغ التجارية لمنتجات نظير الإنسولين الحالية.
JOP/2015/0079A 2014-05-08 2015-04-21 تركيبات إنسولين سريعة المفعول JO3624B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461990402P 2014-05-08 2014-05-08

Publications (1)

Publication Number Publication Date
JO3624B1 true JO3624B1 (ar) 2020-08-27

Family

ID=53189204

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2015/0079A JO3624B1 (ar) 2014-05-08 2015-04-21 تركيبات إنسولين سريعة المفعول

Country Status (35)

Country Link
US (2) US9439952B2 (ar)
EP (3) EP3140008B1 (ar)
JP (1) JP6050902B2 (ar)
KR (1) KR101858890B1 (ar)
CN (1) CN106456717B (ar)
AP (1) AP2016009525A0 (ar)
AR (1) AR100155A1 (ar)
AU (1) AU2015256355B2 (ar)
BR (1) BR112016024357B1 (ar)
CA (1) CA2945188C (ar)
CL (1) CL2016002772A1 (ar)
CY (2) CY1121669T1 (ar)
DK (2) DK3140008T3 (ar)
EA (1) EA031134B1 (ar)
ES (2) ES2891983T3 (ar)
HR (2) HRP20190777T1 (ar)
HU (2) HUE044370T2 (ar)
IL (1) IL248350B (ar)
JO (1) JO3624B1 (ar)
LT (2) LT3536380T (ar)
MA (1) MA39441A1 (ar)
ME (1) ME03384B (ar)
MX (1) MX367521B (ar)
NZ (1) NZ724919A (ar)
PE (1) PE20161408A1 (ar)
PH (1) PH12016502195A1 (ar)
PL (2) PL3140008T3 (ar)
PT (2) PT3536380T (ar)
RS (2) RS62291B1 (ar)
SG (1) SG11201608424WA (ar)
SI (2) SI3536380T1 (ar)
TN (1) TN2016000443A1 (ar)
TR (1) TR201906843T4 (ar)
TW (1) TWI685348B (ar)
WO (1) WO2015171484A1 (ar)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2571857C2 (ru) 2008-03-18 2015-12-20 Ново Нордиск А/С Стабилизированные по отношению к протеазам ацилированные аналоги инсулина
JP6322642B2 (ja) 2012-11-13 2018-05-09 アドシア 置換されたアニオン性化合物を含有する速効型インスリン製剤
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US9371264B2 (en) 2013-01-11 2016-06-21 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
EP3328388B1 (en) * 2015-07-28 2023-12-27 Eli Lilly and Company A pharmaceutical preparation for improving absorption and postprandial hypoglycemic action of insulin
JO3749B1 (ar) * 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
JP2019504684A (ja) * 2016-01-29 2019-02-21 マンカインド コーポレイション 乾燥粉末吸入器
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
JP7220650B2 (ja) 2016-09-26 2023-02-10 ユナイテッド セラピューティクス コーポレイション トレプロスチニルプロドラッグ
CN109803639B (zh) 2016-09-29 2024-01-02 艾瑞克有限公司 新制剂
HRP20221324T1 (hr) 2016-12-16 2022-12-23 Novo Nordisk A/S Farmaceutski pripravci koji sadrže inzulin
GB201707189D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707188D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707187D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
MX2019014195A (es) * 2017-06-01 2020-01-27 Lilly Co Eli Composiciones de insulina de rapida accion.
EP3773472A1 (en) 2018-04-04 2021-02-17 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
CA3094308A1 (en) 2018-04-04 2019-10-10 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
EP3773474A1 (en) 2018-04-04 2021-02-17 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
FR3083985A1 (fr) 2018-07-23 2020-01-24 Adocia Dispositif pour injecter une solution d'insuline(s)
WO2019243627A1 (fr) 2018-06-23 2019-12-26 Adocia Dispositif pour injecter une solution d'insuline(s)
MX2021003090A (es) * 2018-09-18 2021-05-12 Lilly Co Eli Sal de erbumina de treprostinil.
US10799564B1 (en) 2019-05-06 2020-10-13 Baxter International Inc. Insulin premix formulation and product, methods of preparing same, and methods of using same
US11634443B2 (en) 2019-08-23 2023-04-25 United Therapeutics Corporation Treprostinil prodrugs
GB202004814D0 (en) 2020-04-01 2020-05-13 Arecor Ltd Novel formulations
WO2021211916A1 (en) 2020-04-17 2021-10-21 United Therapeutics Corporation Treprostinil for use in the treatment of intersitial lung disease
JP2023529828A (ja) 2020-06-09 2023-07-12 ユナイテッド セラピューティクス コーポレイション トレプロスチニルのフマリルジケトピペリジンプロドラッグ
TW202214292A (zh) * 2020-06-30 2022-04-16 大陸商江蘇恆瑞醫藥股份有限公司 速效胰島素組成物及其醫藥用途
JP2023553989A (ja) 2020-12-14 2023-12-26 ユナイテッド セラピューティクス コーポレイション トレプロスチニルプロドラッグで疾患を治療する方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2740953A1 (de) 1977-09-12 1979-03-22 Thera Ges Fuer Patente Verwendung von prostaglandinen zur senkung des blutzuckerspiegels
JPH10251146A (ja) 1997-03-11 1998-09-22 Toray Ind Inc 糖尿病性神経障害の治療方法
EP1432430A4 (en) * 2001-08-28 2006-05-10 Lilly Co Eli PREMIXTURES OF GLP-1 AND BASALINSULIN
ES2360182T3 (es) * 2002-05-07 2011-06-01 Novo Nordisk A/S Formulaciones solubles que comprenden insulina monomérica e insulina acilada.
US7879909B2 (en) 2004-04-12 2011-02-01 United Therapeutics Corporation Use of Treprostinil to treat neuropathic diabetic foot ulcers
CA2697057A1 (en) * 2007-08-22 2009-02-26 Gilead Colorado, Inc. Therapy for complications of diabetes
WO2010023666A2 (en) 2008-08-28 2010-03-04 Medingo Ltd. Device and method for enhanced subcutaneous insulin absorption
KR20110081204A (ko) * 2008-09-25 2011-07-13 아라다임 코포레이션 트레프로스티닐의 폐 심부 전달
DK2340033T3 (da) 2009-06-26 2014-01-20 Novo Nordisk As Præparat, der omfatter insulin, nicotinamid og arginin
WO2011059053A1 (ja) * 2009-11-13 2011-05-19 東レ株式会社 糖尿病の治療または予防薬
KR20140030125A (ko) 2010-12-14 2014-03-11 노보 노르디스크 에이/에스 인슐린, 니코틴아미드 및 아미노산을 포함하는 제제
MX349950B (es) * 2011-08-12 2017-08-22 Ascendis Pharma As Profarmacos de treprostinil enlazados a un portador.
US9381247B2 (en) * 2012-04-16 2016-07-05 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
US20150065423A1 (en) 2013-08-30 2015-03-05 Perosphere, Inc. Rapid acting injectable formulations
US20150273022A1 (en) 2014-02-10 2015-10-01 Biodel Inc. Stabilized ultra-rapid-acting insulin formulations

Also Published As

Publication number Publication date
RS62291B1 (sr) 2021-09-30
CN106456717A (zh) 2017-02-22
HUE044370T2 (hu) 2019-10-28
US20160129087A1 (en) 2016-05-12
US9439952B2 (en) 2016-09-13
MA39441A1 (fr) 2017-06-30
CA2945188C (en) 2018-12-11
TWI685348B (zh) 2020-02-21
EP3536380B1 (en) 2021-07-07
RS58726B1 (sr) 2019-06-28
SI3536380T1 (sl) 2021-09-30
EP3536380A1 (en) 2019-09-11
ES2733639T3 (es) 2019-12-02
EP3943155A1 (en) 2022-01-26
PH12016502195B1 (en) 2017-02-06
JP6050902B2 (ja) 2016-12-21
BR112016024357A2 (pt) 2017-10-10
EP3140008B1 (en) 2019-04-17
HUE055742T2 (hu) 2021-12-28
PH12016502195A1 (en) 2017-02-06
JP2016523807A (ja) 2016-08-12
DK3140008T3 (da) 2019-06-24
SG11201608424WA (en) 2016-11-29
CA2945188A1 (en) 2015-11-12
AR100155A1 (es) 2016-09-14
TR201906843T4 (tr) 2019-05-21
AP2016009525A0 (en) 2016-10-31
KR20160133567A (ko) 2016-11-22
EA031134B1 (ru) 2018-11-30
TN2016000443A1 (en) 2018-04-04
PL3536380T3 (pl) 2021-12-27
US20160367640A1 (en) 2016-12-22
PL3140008T3 (pl) 2019-09-30
EP3140008A1 (en) 2017-03-15
KR101858890B1 (ko) 2018-05-16
CL2016002772A1 (es) 2017-06-09
AU2015256355A1 (en) 2016-10-27
TW201625291A (zh) 2016-07-16
EA201691911A1 (ru) 2017-02-28
LT3140008T (lt) 2019-05-27
NZ724919A (en) 2018-01-26
MX2016014643A (es) 2017-03-06
AU2015256355B2 (en) 2017-09-14
HRP20190777T1 (hr) 2019-08-23
EP3536380B8 (en) 2021-09-22
MX367521B (es) 2019-08-26
SI3140008T1 (sl) 2019-06-28
CY1124454T1 (el) 2022-07-22
IL248350A0 (en) 2016-11-30
DK3536380T3 (da) 2021-08-02
WO2015171484A1 (en) 2015-11-12
ME03384B (me) 2020-01-20
PT3140008T (pt) 2019-06-25
US10172922B2 (en) 2019-01-08
CN106456717B (zh) 2020-01-17
LT3536380T (lt) 2021-08-10
BR112016024357B1 (pt) 2022-08-23
ES2891983T3 (es) 2022-02-01
CY1121669T1 (el) 2020-07-31
PT3536380T (pt) 2021-09-02
PE20161408A1 (es) 2016-12-28
HRP20211415T1 (hr) 2021-12-10
IL248350B (en) 2020-03-31

Similar Documents

Publication Publication Date Title
PH12016502195B1 (en) Rapid- acting insulin compositions
PH12018500422A1 (en) Rapid-acting insulin compositions
MX2016008978A (es) Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
PH12017500836A1 (en) Transdermal formulations
EP3341404A4 (en) NOVEL INSULIN ANALOGUES AND THEIR USE
EP3110891A4 (en) Low-voc compositions and methods of making and using the same
EP3618840C0 (en) STABLE INSULIN FORMULATIONS
IL280690A (en) Pharmaceutical preparations that include DGLA and their use
EP3285758A4 (en) Co-crystal composition and its pharmaceutical use
MX2017000862A (es) Formulacion de factor viii.
GEP20196977B (en) Pharmaceutical formulations of vildagliptin
IL252683A0 (en) Pyridyl-cycloalkyl-substituted carboxylic acids, preparations containing them and their medical uses
EP3177687B8 (en) Elastomeric compositions comprising usnic acid and devices made thereof or coated therewith
SG11201608845PA (en) Cosmetic composition containing mentha haplocalyx as active ingredient
IL262729A (en) Compositions and methods of providing thyroid hormone or analogs thereof
GB201401706D0 (en) Nanoparticle-insulin and insulin analogue compositions
SA519410672B1 (ar) تركيبات إنسولين سريعة المفعول
EP3452077A4 (en) COMPOSITIONS AND METHODS FOR PROVIDING THYROID HORMONE OR THE LIKE THEREOF